BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company dedicated to developing and commercializing innovative therapies for rare and life-threatening genetic diseases. The company's robust portfolio addresses significant unmet medical needs across various therapeutic areas, including lysosomal storage disorders, achondroplasia, phenylketonuria, hemophilia A, and Batten disease. Key marketed products include Vimizim for MPS IV A, Voxzogo for achondroplasia, Naglazyme for MPS VI, Palynziq for phenylketonuria, Brineura for CLN2, Aldurazyme for MPS I, Kuvan for phenylketonuria, and Roctavian for severe hemophilia A. BioMarin's business model centers on identifying and advancing novel treatments for conditions that often lack effective therapeutic options, leveraging its expertise in enzyme replacement therapies, gene therapies, and other advanced modalities. The company's strategic focus is on expanding its pipeline through internal research and development, as well as strategic collaborations, with promising candidates in areas such as growth disorders and alpha-1 antitrypsin deficiency liver disease. BioMarin reaches its patient populations through a specialized distribution network comprising specialty pharmacies, hospitals, and international government agencies and distributors, ensuring access to its critical treatments worldwide.